
  
    
      
        Background_NNP
        The_DT p_NN 53_CD tumor_NN suppressor_NN gene_NN is_VBZ activated_VBN during_IN
        several_JJ cellular_JJ processes_NNS ._. These_DT include_VBP DNA_NNP damage_NN caused_VBN
        by_IN Ionizing_NNP Radiation_NNP and_CC genotoxic_JJ agents_NNS [_NN 1_CD ]_NN ,_, by_IN
        expression_NN of_IN activated_VBN oncogenes_NNS such_JJ as_IN ras_NNS or_CC myc_NN [_NN 2_CD ]_NN ,_,
        or_CC during_IN progression_NN of_IN primary_JJ cells_NNS to_TO senescence_NN [_NN 3_CD ]_NN ._.
        The_DT activation_NN of_IN p_NN 53_CD by_IN these_DT diverse_JJ stimuli_NNS can_MD initiate_VB
        either_CC growth_VB arrest_NN or_CC apoptosis_NNS depending_VBG on_IN the_DT cellular_JJ
        context_NN [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ._. p_NN 53_CD posses_NNS sequence-specific_JJ DNA_NNP
        binding_JJ activity_NN and_CC functions_NNS in_IN the_DT cell_NN as_IN a_DT
        transcriptional_NN regulator_NN ._. Many_JJ p_NN 53_CD regulated_VBN genes_NNS have_VBP
        been_VBN identified_VBN [_NN 3_CD ,_, 4_CD ,_, 5_CD ]_NN ,_, and_CC the_DT majority_NN of_IN the_DT
        cellular_JJ effects_NNS of_IN p_NN 53_CD activation_NN can_MD be_VB attributed_VBN to_TO the_DT
        activation_NN of_IN these_DT p_NN 53_CD target_NN genes_NNS ._.
        The_DT mechanism_NN of_IN p_NN 53_CD activation_NN in_IN response_NN to_TO either_CC
        DNA_NNP damage_NN or_CC oncogene_NN expression_NN occurs_VBZ through_IN
        stabilization_NN of_IN the_DT p_NN 53_CD protein_NN ._. In_IN unstimulated_JJ cells_NNS ,_,
        the_DT mdm_NN 2_CD protein_NN binds_NNS to_TO the_DT N-_NNP terminal_NN transactivation_NN
        domain_NN of_IN p_NN 53_CD and_CC targets_NNS it_PRP for_IN ubiquitin-dependent_JJ
        degradation_NN [_NN 6_CD ,_, 7_CD ]_NN ._. Activation_NNP of_IN p_NN 53_CD requires_VBZ disruption_NN
        of_IN the_DT mdm_NN 2_CD -_: p_NN 53_CD interaction_NN to_TO allow_VB p_NN 53_CD accumulation_NN in_IN
        the_DT cell_NN ._. 2_LS distinct_JJ mechanisms_NNS for_IN p_NN 53_CD activation_NN have_VBP so_RB
        far_RB been_VBN elucidated_JJ ._. The_DT expression_NN of_IN oncogenes_NNS such_JJ as_IN
        ras_NNS in_IN untransformed_JJ cells_NNS stimulates_NNS transcription_NN of_IN the_DT
        p_NN 14_CD Arfgene_NNP [_NN 2_CD ]_NN ._. p_NN 14_CD Arfbinds_NNP to_TO and_CC sequesters_NNS mdm_NN 2_CD ,_,
        allowing_VBG free_JJ p_NN 53_CD protein_NN to_TO accumulate_VBP in_IN the_DT cells_NNS [_NN 8_CD ]_NN ._.
        Activation_NNP of_IN p_NN 53_CD by_IN DNA_NNP damage_NN is_VBZ also_RB brought_VBN about_IN by_IN
        inhibition_NN of_IN p_NN 53_CD -_: mdm_NN 2_CD interaction_NN ._. The_DT product_NN of_IN the_DT
        Ataxia_NNP Telangiectasia_NNP gene_NN ,_, the_DT ATM_NNP protein_NN kinase_NN [_NN 9_CD ]_NN ,_,
        directly_RB phosphorylates_NNS serine_NN 15_CD of_IN the_DT p_NN 53_CD protein_NN in_IN
        response_NN to_TO Ionizing_NNP Radiation_NNP [_NN 10_CD ,_, 11_CD ]_NN ._. In_IN addition_NN ,_, ATM_NNP
        phosphorylates_NNS and_CC activates_NNS chk_NN 2_CD kinase_NN [_NN 12_CD ]_NN ._. Activated_NNP
        chk_NN 2_CD can_MD then_RB directly_RB phosphorylate_NN serine_NN 20_CD of_IN p_NN 53_CD [_NN 13_CD ,_,
        14_CD ]_NN ._. ATM_NNP therefore_RB controls_VBZ the_DT phosphorylation_NN of_IN serines_NNS
        15_CD and_CC 20_CD of_IN p_NN 53_CD ._. In_IN addition_NN ,_, DNA_NNP damage_NN increases_VBZ the_DT
        phosphorylation_NN of_IN serines_NNS 33_CD and_CC 37_CD of_IN p_NN 53_CD through_IN an_DT
        ATM-independent_NNP mechanism_NN [_NN 15_CD ,_, 16_CD ,_, 17_CD ,_, 18_CD ]_NN ._. These_DT DNA_NNP
        damage-induced_JJ phosphorylations_NNS of_IN p_NN 53_CD block_VB the_DT binding_JJ of_IN
        mdm_NN 2_CD to_TO the_DT N-_NNP terminal_NN of_IN the_DT p_NN 53_CD protein_NN [_NN 18_CD ]_NN ._. Thus_RB
        phosphorylation_NN of_IN the_DT p_NN 53_CD protein_NN in_IN response_NN to_TO DNA_NNP
        damage_NN or_CC expression_NN of_IN p_NN 14_CD Arf_NNP prevents_VBZ mdm_NN 2_CD binding_JJ and_CC
        p_NN 53_CD protein_NN then_RB accumulates_NNS in_IN the_DT cell_NN ._.
        Although_IN stabilization_NN of_IN the_DT p_NN 53_CD protein_NN is_VBZ the_DT initial_JJ
        step_NN in_IN p_NN 53_CD activation_NN ,_, subsequent_JJ steps_NNS ,_, including_VBG
        activation_NN of_IN p_NN 53_CD 's_POS DNA_NNP binding_JJ activity_NN and_CC changes_NNS in_IN
        p_NN 53_CD 's_POS transcriptional_NN activity_NN ,_, are_VBP also_RB involved_VBN ._. For_IN
        example_NN ,_, p_NN 53_CD 's_POS DNA_NNP binding_JJ activity_NN is_VBZ increased_VBN by_IN the_DT DNA_NNP
        damage-induced_JJ acetylation_NN of_IN the_DT C-_NNP terminal_NN of_IN p_NN 53_CD [_NN 16_CD ,_,
        19_CD ]_NN ,_, and_CC this_DT acetylation_NN requires_VBZ the_DT prior_JJ
        phosphorylation_NN of_IN the_DT N-_NNP terminal_NN of_IN p_NN 53_CD [_NN 16_CD ]_NN ._. In_IN
        addition_NN ,_, phosphorylation_NN of_IN the_DT N-_NNP terminal_NN transactivation_NN
        domain_NN of_IN p_NN 53_CD may_MD be_VB required_VBN to_TO stimulate_VB transcriptional_NN
        activation_NN of_IN p_NN 53_CD target_NN genes_NNS ._. Multiple_NNP phosphorylation_NN
        sites_NNS have_VBP been_VBN detected_VBN in_IN the_DT N-_NNP terminal_NN of_IN p_NN 53_CD ,_,
        including_VBG serines_NNS 6_CD ,_, 9_CD ,_, 15_CD ,_, 20_CD ,_, 33_CD ,_, 37_CD and_CC 46_CD [_NN 10_CD ,_, 11_CD ,_, 12_CD ,_,
        13_CD ,_, 14_CD ,_, 20_CD ,_, 21_CD ,_, 22_CD ]_NN ._. While_IN phosphorylation_NN of_IN serines_NNS 15_CD
        and_CC 20_CD of_IN p_NN 53_CD are_VBP clearly_RB dependent_JJ on_IN the_DT ATM_NNP and_CC chk_NN 2_CD
        protein_NN kinases_NNS [_NN 10_CD ,_, 11_CD ,_, 12_CD ,_, 13_CD ,_, 14_CD ]_NN ,_, the_DT kinases_NNS
        responsible_JJ for_IN phosphorylation_NN of_IN the_DT remaining_VBG serine_NN
        residues_NNS 
        in_IN vivo_NN is_VBZ not_RB clear_JJ ._.
        The_DT activation_NN of_IN p_NN 53_CD by_IN DNA_NNP damage_NN or_CC oncogenes_NNS such_JJ as_IN
        ras_NNS results_NNS in_IN either_DT growth_NN arrest_NN or_CC apoptosis_NNS of_IN the_DT
        affected_VBN cell_NN ._. In_IN this_DT study_NN ,_, we_PRP have_VBP examined_VBN how_WRB Glycogen_NNP
        Synthase_NNP Kinase_NNP 3_CD β_NN (_( GSK_NNP 3_CD β_NN )_) ,_, a_DT protein_NN kinase_NN involved_VBN in_IN
        tumorigenesis_NNS ,_, differentiation_NN and_CC apoptosis_NNS ,_, regulates_VBZ the_DT
        function_NN of_IN p_NN 53_CD [_NN 23_CD ,_, 24_CD ]_NN ._. GSK_NNP 3_CD β_NN phosphorylates_NNS several_JJ
        transcription_NN factors_NNS ,_, including_VBG NFATc_NNP and_CC HSF_NNP 1_CD [_NN 24_CD ,_, 25_CD ,_,
        26_CD ,_, 27_CD ]_NN ._. GSK_NNP 3_CD β_NN is_VBZ constitutively_RB active_JJ in_IN resting_VBG cells_NNS
        but_CC is_VBZ inhibited_VBD when_WRB cells_NNS are_VBP exposed_VBN to_TO growth_VB factors_NNS [_NN
        24_CD ,_, 28_CD ]_NN ._.
        GSK_NNP 3_CD inhibition_NN occurs_VBZ when_WRB the_DT p_NN 110_CD -_: PI_NNP 3_CD -_: kinase_NN /_NN Protein_NNP
        Kinase_NNP B_NNP (_( PKB_NNP )_) pathway_NN is_VBZ activated_VBN by_IN growth_NN factors_NNS [_NN 23_CD ,_,
        24_CD ,_, 25_CD ,_, 29_CD ]_NN ._. Activated_NNP PKB_NNP then_RB phosphorylates_NNS GSK_NNP 3_CD β_NN ,_,
        inhibiting_VBG GSK_NNP 3_CD kinase_NN activity_NN [_NN 29_CD ]_NN ._. This_DT activation_NN of_IN
        the_DT p_NN 110_CD -_: PI_NNP 3_CD -_: kinase_NN /_NN PKB_NNP pathway_NN ,_, and_CC inhibition_NN of_IN GSK_NNP 3_CD ,_,
        delivers_VBZ a_DT strong_JJ anti-apoptotic_JJ signal_NN to_TO the_DT cell_NN [_NN 23_CD ,_,
        24_CD ,_, 25_CD ]_NN ._. Given_VBN the_DT well_NN characterized_VBN role_NN of_IN p_NN 53_CD in_IN
        apoptosis_NNS [_NN 3_CD ,_, 4_CD ,_, 5_CD ]_NN ,_, we_PRP examined_VBD if_IN GSK_NNP 3_CD p_NN participates_VBZ in_IN
        the_DT regulation_NN of_IN the_DT p_NN 53_CD protein_NN ._.
        GSK_NNP 3_CD phosphorylates_NNS the_DT consensus_NN sequence_NN
        Ser-_NNP X-X-X-S_NNP er_UH (_( P_NN )_) ,_, where_WRB the_DT C-_NNP terminal_NN serine_NN residue_NN is_VBZ
        already_RB phosphorylated_JJ [_NN 24_CD ,_, 28_CD ]_NN ._. Thus_RB GSK_NNP 3_CD only_RB
        phosphorylates_NNS target_VBP proteins_NNS which_WDT have_VBP already_RB been_VBN
        phosphorylated_JJ by_IN a_DT separate_JJ ,_, priming_VBG kinase_NN ._. p_NN 53_CD contains_VBZ
        5_CD potential_JJ GSK_NNP 3_CD phosphorylation_NN sites_NNS ,_, 3_CD in_IN the_DT N-_NNP terminal_NN
        transactivation_NN domain_NN and_CC 2_CD in_IN the_DT C-_NNP terminal_NN regulatory_JJ
        domain_NN ._. Here_RB ,_, we_PRP show_VBP that_IN GSK_NNP 3_CD β_NN ,_, but_CC not_RB GSK_NNP 3_CD α_NN ,_, can_MD
        phosphorylate_NN serine_NN 33_CD of_IN p_NN 53_CD 
        in_IN vitro_NN when_WRB serine_NN 37_CD is_VBZ already_RB
        phosphorylated_JJ ._. Further_RB ,_, GSK_NNP 3_CD β_NN can_MD increase_VB p_NN 53_CD 's_POS
        transcriptional_NN activity_NN 
        in_IN vivo_NN ,_, and_CC this_DT activation_NN is_VBZ lost_VBN
        when_WRB serine_NN 33_CD is_VBZ mutated_VBN to_TO alanine_NN ._.
      
      
        Results_NNS
        The_DT p_NN 53_CD protein_NN contains_VBZ several_JJ serine_NN residues_NNS which_WDT
        are_VBP located_VBN within_IN potential_JJ GSK_NNP 3_CD phosphorylation_NN sites_NNS ._.
        Protein_NNP kinases_NNS which_WDT can_MD phosphorylate_NN p_NN 53_CD within_IN these_DT
        predicted_VBN GSK_NNP 3_CD sites_NNS include_VBP MAP_NNP kinase_NN ,_, Protein_NNP Kinase_NNP A_DT ,_,
        Protein_NNP Kinase_NNP C_NNP ,_, Casein_NNP Kinase_NNP II_NNP ,_, Jun_NNP kinase_NN (_( JNK_NNP )_) and_CC
        DNA-dependent_NNP Protein_NNP Kinase_NNP (_( DNA-PK_NNP )_) [_NN 30_CD ,_, 31_CD ,_, 32_CD ,_, 33_CD ,_, 34_CD ,_,
        35_CD ]_NN ._. These_DT kinases_NNS were_VBD examined_VBN to_TO determine_VB if_IN they_PRP can_MD
        act_VB as_IN the_DT priming_VBG kinase_NN for_IN either_DT of_IN the_DT 2_CD isoforms_NNS of_IN
        GSK_NNP 3_CD ,_, GSK_NNP 3_CD α_NN and_CC GSK_NNP 3_CD β_NN ._. The_DT general_JJ protocol_NN was_VBD to_TO incubate_NN
        purified_JJ priming_VBG kinases_NNS with_IN p_NN 53_CD -_: GST_NNP fusion_NN protein_NN and_CC
        ATP_NNP for_IN 5_CD h_NN ,_, then_RB heat_NN inactivate_NN the_DT priming_VBG kinase_NN ._.
        Preliminary_JJ experiments_NNS indicated_VBD that_IN each_DT of_IN the_DT tested_VBN
        kinases_NNS was_VBD able_JJ to_TO phosphorylate_NN p_NN 53_CD -_: GST_NNP under_IN the_DT
        experimental_JJ conditions_NNS (_( data_NNS not_RB shown_VBN )_) ._. Aliquots_NNP of_IN the_DT
        prephosphorylated_JJ p_NN 53_CD -_: GST_NNP were_VBD then_RB incubated_JJ with_IN or_CC
        without_IN recombinant_JJ GSK_NNP 3_CD α_NN or_CC GSK_NNP 3_CD β_NN and_CC 32_CD P-ATP_NNP to_TO measure_VB
        p_NN 53_CD phosphorylation_NN ._.
        p_NN 53_CD -_: GST_NNP preincubated_JJ in_IN buffer_NN alone_RB ,_, and_CC then_RB exposed_VBN
        to_TO the_DT heat_NN inactivation_NN protocol_NN was_VBD not_RB phosphorylated_JJ by_IN
        either_DT GSK_NNP 3_CD α_NN or_CC GSK_NNP 3_CD β_NN (_( fig_NN 1_CD ,_, Control_NNP )_) ._. Autophosphorylation_NNP
        of_IN GSK_NNP 3_CD α_NN and_CC GSK_NNP 3_CD β_NN can_MD be_VB seen_VBN (_( figure_NN 1_LS )_) ._. Unphosphorylated_NNP
        p_NN 53_CD -_: GST_NNP is_VBZ therefore_RB not_RB a_DT substrate_NN for_IN GSK_NNP 3_CD α_NN or_CC GSK_NNP 3_CD β_NN 
        in_IN vitro_NN ._. p_NN 53_CD -_: GST_NNP was_VBD then_RB
        prephosphorylated_JJ with_IN MAP_NNP kinase_NN ,_, S_NNP 6_CD kinase_NN ,_, Protein_NNP
        Kinase_NNP A_DT ,_, DNA-PK_NNP and_CC Protein_NNP Kinase_NNP C_NNP (_( fig_NN 1_LS )_) or_CC Casein_NNP
        Kinase_NNP II_NNP and_CC JNK_NNP 1_CD /_NN JNK_NNP 2_CD (_( data_NNS not_RB shown_VBN )_) ._. Following_VBG
        incubation_NN in_IN each_DT of_IN the_DT primary_JJ kinases_NNS ,_, the_DT
        prephosphorylated_JJ p_NN 53_CD -_: GST_NNP was_VBD then_RB incubated_JJ with_IN 32_CD P-ATP_NNP
        and_CC either_CC GSK_NNP 3_CD α_NN or_CC GSK_NNP 3_CD β_NN ._. Prephosphorylation_NNP of_IN p_NN 53_CD -_: GST_NNP by_IN
        MAP_NNP kinase_NN ,_, S_NNP 6_CD kinase_NN ,_, Protein_NNP Kinase_NNP A_DT or_CC Protein_NNP Kinase_NNP C_NNP
        (_( fig_NN 1_LS )_) or_CC Casein_NNP Kinase_NNP II_NNP or_CC JNK_NNP 1_CD or_CC JNK_NNP 2_CD (_( data_NNS not_RB
        shown_VBN )_) failed_VBD to_TO create_VB a_DT phosphorylation_NN site_NN for_IN either_DT
        GSK_NNP 3_CD α_NN or_CC GSK_NNP 3_CD β_NN ._. However_RB ,_, prephosphorylation_NN of_IN p_NN 53_CD -_: GST_NNP by_IN
        DNA-PK_NNP resulted_VBD in_IN strong_JJ phosphorylation_NN of_IN p_NN 53_CD by_IN GSK_NNP 3_CD β_NN
        (_( fig_NN 1_LS )_) but_CC not_RB GSK_NNP 3_CD α_NN ._. GST_NNP protein_NN alone_RB incubated_JJ with_IN
        DNA-PK_NNP was_VBD not_RB phosphorylated_JJ by_IN GSK_NNP 3_CD β_NN (_( data_NNS not_RB shown_VBN )_) ._.
        Since_IN there_EX was_VBD no_DT significant_JJ phosphorylation_NN of_IN p_NN 53_CD -_: GST_NNP
        by_IN GSK_NNP 3_CD α_NN (_( fig_NN 1_LS )_) ,_, this_DT indicates_VBZ that_DT phosphorylation_NN of_IN
        p_NN 53_CD by_IN DNA-PK_NNP ,_, 
        in_IN vitro_NN ,_, creates_VBZ a_DT site_NN for_IN GSK_NNP 3_CD β_NN to_TO
        phosphorylate_NN p_NN 53_CD ._.
        Next_JJ ,_, we_PRP set_VBD out_IN to_TO identify_VB the_DT exact_JJ amino-acid_JJ (_( s_VBZ )_)
        within_IN the_DT p_NN 53_CD protein_NN which_WDT were_VBD phosphorylated_JJ by_IN GSK_NNP 3_CD β_NN ._.
        p_NN 53_CD is_VBZ phosphorylated_JJ by_IN DNA-PK_NNP at_IN serines_NNS 15_CD and_CC 37_CD [_NN 32_CD ]_NN ._.
        Of_IN these_DT 2_CD sites_NNS ,_, the_DT sequence_NN around_IN serine_NN 37_CD contains_VBZ a_DT
        predicted_VBN GSK_NNP 3_CD phosphorylation_NN site_NN at_IN serine_NN 33_CD (_( figure_NN 2_CD ,_,
        underlined_VBD )_) ._. Serine_NNP 33_CD and_CC 37_CD of_IN p_NN 53_CD were_VBD individually_RB
        mutated_VBN to_TO alanine_NN ,_, and_CC p_NN 53_CD -_: GST_NNP fusion_NN proteins_NNS containing_VBG
        these_DT mutations_NNS prepared_VBN ._. The_DT ability_NN of_IN DNA-PK_NNP to_TO create_VB a_DT
        GSK_NNP 3_CD β_NN phosphorylation_NN site_NN on_IN these_DT p_NN 53_CD proteins_NNS was_VBD then_RB
        examined_VBN ._.
        In_IN the_DT absence_NN of_IN p_NN 53_CD ,_, no_DT phosphorylation_NN by_IN GSK_NNP 3_CD β_NN was_VBD
        detected_VBN (_( fig_NN 2_LS )_) ._. Unphosphorylated_NNP p_NN 53_CD -_: GST_NNP was_VBD not_RB a_DT
        substrate_NN for_IN GSK_NNP 3_CD β_NN ,_, whereas_IN p_NN 53_CD -_: GST_NNP prephosphorylated_JJ by_IN
        DNA-PK_NNP was_VBD (_( fig_NN 2_LS )_) ._. Mutation_NNP of_IN serine_NN 33_CD of_IN p_NN 53_CD to_TO alanine_NN
        (_( S_NNP 33_CD A_DT )_) blocked_VBD the_DT ability_NN of_IN GSK_NNP 3_CD β_NN to_TO phosphorylate_NN p_NN 53_CD ,_,
        indicating_VBG that_DT serine_NN 33_CD is_VBZ the_DT likely_JJ target_NN for_IN GSK_NNP 3_CD β_NN
        (_( fig_NN 2_CD ,_, 33_CD )_) ._. Similarly_RB ,_, mutation_NN of_IN serine_NN 37_CD ,_, which_WDT
        abolishes_NNS the_DT DNA-PK_NNP phosphorylation_NN site_NN ,_, blocks_NNS
        phosphorylation_NN of_IN p_NN 53_CD by_IN GSK_NNP 3_CD β_NN ._. This_DT indicates_VBZ that_DT p_NN 53_CD
        must_MD be_VB phosphorylated_JJ on_IN serine_NN 37_CD by_IN DNA-PK_NNP before_IN it_PRP can_MD
        be_VB phosphorylated_JJ at_IN serine_NN 33_CD by_IN GSK_NNP 3_CD β_NN ._.
        To_TO examine_VB the_DT 
        in_IN vivo_NN function_NN of_IN these_DT 
        in_IN vitro_NN phosphorylations_NNS ,_, wtp_NN 53_CD and_CC
        p_NN 53_CD with_IN the_DT S_NNP 33_CD A_DT and_CC S_NNP 37_CD A_DT mutations_NNS were_VBD sub-cloned_JJ into_IN
        the_DT expression_NN vector_NN pcDNA_NN 3_CD ._. 1_LS ._. These_DT were_VBD then_RB expressed_VBN
        in_IN the_DT human_JJ osteosarcoma_NN cell_NN line_NN SAOS-_NNP 2_CD ,_, which_WDT does_VBZ not_RB
        express_VB endogenous_JJ p_NN 53_CD protein_NN [_NN 33_CD ]_NN ._. First_LS ,_, we_PRP analyzed_VBD
        the_DT level_NN of_IN expression_NN of_IN each_DT of_IN the_DT p_NN 53_CD proteins_NNS
        following_VBG transient_JJ expression_NN in_IN SAOS-_NNP 2_CD cells_NNS ._. In_IN fig_NN 3_CD A_DT ,_,
        approx_NN equal_JJ amounts_NNS of_IN wtp_NN 53_CD ,_, p_NN 53_CD S_NNP 33_CD A_DT and_CC p_NN 53_CD S_NNP 37_CD A_DT were_VBD
        detected_VBN by_IN western_JJ blot_NN ,_, indicating_VBG that_IN they_PRP were_VBD
        expressed_VBN at_IN similar_JJ levels_NNS ._. In_IN fig_NN 3_CD B_NNP ,_, we_PRP examined_VBD the_DT
        transcriptional_NN activity_NN of_IN these_DT p_NN 53_CD constructs_NNS ._. A_DT
        p_NN 53_CD -_: reporter_NN construct_VB ,_, p_NN 50_CD -_: 2_CD ,_, which_WDT specifically_RB responds_VBZ
        to_TO wtp_NN 53_CD by_IN increasing_VBG transcription_NN of_IN the_DT luciferase_NN
        gene_NN ,_, was_VBD used_VBN [_NN described_VBD in_IN 33_CD ]_NN ._. In_IN fig_NN 3_CD B_NNP ,_, SAOS-_NNP 2_CD cells_NNS
        transiently_RB expressing_VBG vector_NN (_( Con_NN )_) ,_, showed_VBD minimal_JJ
        activation_NN of_IN the_DT p_NN 53_CD -_: reporter_NN construct_VB ._. Cells_NNP expressing_VBG
        wtp_NN 53_CD showed_VBD significant_JJ activation_NN ,_, as_IN did_VBD cells_NNS
        expressing_VBG both_DT the_DT S_NNP 33_CD A_DT and_CC S_NNP 37_CD A_DT mutations_NNS ._. Both_DT the_DT S_NNP 33_CD A_DT
        and_CC S_NNP 37_CD A_DT mutations_NNS displayed_VBN slightly_RB higher_JJR basal_NN levels_NNS
        of_IN transcriptional_NN activity_NN than_IN the_DT wtp_NN 53_CD protein_NN ._.
        Serines_NNP 33_CD and_CC 37_CD are_VBP located_VBN within_IN the_DT N-_NNP terminal_NN
        transcriptional_NN activation_NN domain_NN of_IN the_DT p_NN 53_CD protein_NN ._. To_TO
        determine_VB if_IN GSK_NNP 3_CD β_NN regulates_VBZ p_NN 53_CD 's_POS transcriptional_NN activity_NN
        
        in_IN vivo_NN ,_, a_DT wild_JJ type_NN GSK_NNP 3_CD β_NN expression_NN
        vector_NN was_VBD cotransfected_JJ with_IN either_DT wtp_NN 53_CD or_CC p_NN 53_CD with_IN
        mutations_NNS in_IN serines_NNS 33_CD or_CC 37_CD ._. The_DT ability_NN of_IN GSK_NNP 3_CD β_NN to_TO
        activate_VBP each_DT construct_VB was_VBD calculated_VBN by_IN expressing_VBG the_DT
        p_NN 53_CD transcriptional_NN activity_NN in_IN the_DT presence_NN of_IN GSK_NNP 3_CD β_NN as_IN a_DT
        percentage_NN of_IN that_DT observed_VBD in_IN the_DT absence_NN of_IN GSK_NNP 3_CD β_NN ._. On_IN
        this_DT scale_NN ,_, no_DT activation_NN by_IN GSK_NNP 3_CD β_NN yields_VBZ a_DT zero_CD percent_NN
        increase_NN in_IN p_NN 53_CD transcriptional_NN relative_JJ to_TO p_NN 53_CD alone_RB ._.
        GSK_NNP 3_CD β_NN alone_RB (_( fig_NN 3_CD C_NNP ,_, Con_NN )_) did_VBD not_RB significantly_RB increase_VB
        the_DT activity_NN of_IN the_DT luciferase_NN reporter_NN construct_VB ._. When_WRB
        GSK_NNP 3_CD β_NN was_VBD cotransfected_JJ with_IN wtp_NN 53_CD ,_, p_NN 53_CD -_: dependent_JJ activity_NN
        from_IN the_DT luciferase_NN reporter_NN construct_VB was_VBD increased_VBN by_IN
        160_CD %_NN compared_VBN to_TO wtp_NN 53_CD alone_RB ._. To_TO determine_VB if_IN this_DT
        activation_NN of_IN p_NN 53_CD transcriptional_NN activity_NN required_VBD the_DT
        GSK_NNP 3_CD β_NN phosphorylation_NN site_NN at_IN serine_NN 33_CD ,_, wtp_NN 53_CD with_IN serine_NN
        to_TO alanine_NN mutations_NNS at_IN either_DT positions_NNS 33_CD or_CC 37_CD were_VBD
        cotransfected_JJ with_IN GSK_NNP 3_CD β_NN ._. Mutation_NNP of_IN either_DT serine_NN 33_CD or_CC
        37_CD significantly_RB reduced_VBD the_DT ability_NN of_IN GSK_NNP 3_CD β_NN to_TO upregulate_NN
        p_NN 53_CD transcriptional_NN activity_NN ._. This_DT is_VBZ consistent_JJ with_IN the_DT
        phosphorylation_NN data_NN in_IN fig_NN 1_CD and_CC 2_CD ,_, which_WDT indicated_VBD that_DT
        serine_NN 37_CD phosphorylation_NN is_VBZ required_VBN for_IN the_DT subsequent_JJ
        phosphorylation_NN of_IN serine_NN 33_CD by_IN GSK_NNP 3_CD β_NN ._. These_DT results_NNS
        suggests_VBZ that_IN GSK_NNP 3_CD β_NN may_MD be_VB a_DT physiological_JJ regulator_NN of_IN the_DT
        p_NN 53_CD protein_NN ._. GSK_NNP 3_CD β_NN is_VBZ constitutively_RB active_JJ in_IN resting_VBG
        cells_NNS ,_, and_CC is_VBZ inactivated_JJ by_IN PKB_NNP through_IN the_DT growth_NN factor_NN
        dependent_JJ p_NN 110_CD -_: PI_NNP 3_CD -_: kinase_NN pathway_NN [_NN 25_CD ,_, 28_CD ,_, 29_CD ]_NN ._. Thus_RB the_DT
        activity_NN of_IN GSK_NNP 3_CD β_NN in_IN growing_VBG cells_NNS is_VBZ less_JJR than_IN that_DT in_IN
        cells_NNS arrested_VBN in_IN Go_VB ._. p_NN 53_CD can_MD be_VB activated_VBN by_IN several_JJ
        distinct_JJ pathways_NNS ,_, including_VBG DNA_NNP damage_NN ._. If_IN GSK_NNP 3_CD β_NN is_VBZ
        involved_VBN in_IN the_DT activation_NN of_IN p_NN 53_CD by_IN DNA_NNP damage_NN ,_, then_RB GSK_NNP 3_CD β_NN
        is_VBZ predicted_VBN to_TO be_VB upregulated_JJ in_IN response_NN to_TO DNA_NNP damage_NN ._.
        In_IN fig_NN 4_CD ,_, GSK_NNP 3_CD β_NN kinase_NN activity_NN was_VBD monitored_VBN by_IN
        immunoprecipitating_VBG GSK_NNP 3_CD β_NN and_CC then_RB measuring_VBG the_DT ability_NN of_IN
        the_DT immunoprecipitated_JJ protein_NN to_TO phosphorylate_NN a_DT specific_JJ
        GSK_NNP 3_CD β_NN peptide_NN substrate_NN ._. In_IN fig_NN 4_CD ,_, the_DT omission_NN of_IN either_DT
        the_DT peptide_NN or_CC the_DT GSK_NNP 3_CD β_NN antibody_NN from_IN the_DT assay_NN resulted_VBD
        in_IN minimal_JJ phosphorylation_NN of_IN the_DT substrate_NN peptide_NN (_( fig_NN
        4_LS )_) ._. When_WRB both_DT GSK_NNP 3_CD β_NN antibody_NN and_CC substrate_NN peptide_NN were_VBD
        employed_VBN ,_, high_JJ levels_NNS of_IN GSK_NNP 3_CD β-dependent_JJ kinase_NN activity_NN
        were_VBD detected_VBN ._. When_WRB cells_NNS were_VBD incubated_JJ for_IN 24_CD h_NN in_IN low_JJ
        serum_NN (_( 0_CD ._. 5_LS %_NN )_) to_TO induce_VB growth_NN arrest_NN in_IN Go_VB ,_, the_DT levels_NNS of_IN
        GSK_NNP 3_CD β_NN activity_NN were_VBD increased_VBN compared_VBN to_TO asynchronously_RB
        growing_VBG cells_NNS (_( fig_NN 4_CD ,_, Go_VB )_) ._. When_WRB asynchronously_RB growing_VBG
        cells_NNS were_VBD exposed_VBN to_TO 5_CD Gy_NNP or_CC 10_CD Gy_NNP of_IN Ionizing_NNP Radiation_NNP to_TO
        cause_VB DNA_NNP damage_NN ,_, the_DT levels_NNS of_IN GSK_NNP 3_CD β_NN activity_NN were_VBD
        reduced_VBN ._. Similar_JJ results_NNS were_VBD seen_VBN using_VBG p_NN 53_CD -_: GST_NNP as_IN the_DT
        substrate_NN for_IN GSK_NNP 3_CD β_NN phosphorylation_NN in_IN the_DT kinase_NN assay_NN
        (_( data_NNS not_RB shown_VBN )_) ._. This_DT implies_VBZ that_IN the_DT phosphorylation_NN of_IN
        serine_NN 33_CD of_IN p_NN 53_CD by_IN GSK_NNP 3_CD β_NN would_MD be_VB decreased_VBN in_IN cells_NNS
        exposed_VBN to_TO DNA_NNP damage_NN ,_, but_CC elevated_VBD in_IN cells_NNS growth_NN
        arrested_VBN in_IN Go_VB ._.
      
      
        Discussion_NNP
        Several_JJ p_NN 53_CD kinases_NNS were_VBD examined_VBN for_IN their_PRP$ ability_NN to_TO
        create_VB 
        in_IN vitro_NN GSK_NNP 3_CD phosphorylation_NN sites_NNS
        on_IN p_NN 53_CD ._. Phosphorylation_NNP of_IN p_NN 53_CD by_IN DNA-PK_NNP created_VBD a_DT
        phosphorylation_NN site_NN for_IN GSK_NNP 3_CD β_NN ,_, but_CC not_RB for_IN GSK_NNP 3_CD α_NN ._. GSK_NNP 3_CD α_NN
        and_CC GSK_NNP 3_CD β_NN have_VBP 98_CD %_NN homology_NN within_IN the_DT kinase_NN domain_NN ,_,
        although_IN regions_NNS N-_NNP and_CC C-_NNP terminal_NN to_TO this_DT are_VBP less_RBR well_RB
        conserved_JJ [_NN 36_CD ]_NN ._. GSK_NNP 3_CD α_NN and_CC GSK_NNP 3_CD β_NN have_VBP similar_JJ substrate_NN
        specificity_NN 
        in_IN vivo_NN ,_, and_CC are_VBP regulated_VBN in_IN
        parallel_JJ in_IN response_NN to_TO growth_VB factors_NNS [_NN 24_CD ,_, 27_CD ,_, 28_CD ,_, 29_CD ]_NN ._.
        However_RB ,_, disruption_NN of_IN GSK_NNP 3_CD β_NN in_IN mice_NNS results_NNS in_IN embryonic_JJ
        lethality_NN and_CC impaired_VBN NFκ_NNP B_NNP function_NN [_NN 37_CD ]_NN ,_, indicating_VBG
        that_IN GSK_NNP 3_CD α_NN cannot_NN substitute_NN for_IN GSK_NNP 3_CD β_NN in_IN this_DT model_NN
        system_NN ._. GSK_NNP 3_CD α_NN and_CC GSK_NNP 3_CD β_NN therefore_RB have_VBP overlapping_VBG cellular_JJ
        functions_NNS ,_, but_CC each_DT isoform_NN also_RB regulates_VBZ distinct_JJ
        signaling_VBG pathways_NNS ._. Our_PRP$ results_NNS clearly_RB show_VBP that_DT p_NN 53_CD
        phsophorylation_NN is_VBZ specific_JJ for_IN GSK_NNP 3_CD β_NN ._.
        The_DT GSK_NNP 3_CD β_NN phosphorylation_NN site_NN was_VBD identified_VBN by_IN
        mutagenesis_NNS as_IN serine_NN 33_CD of_IN p_NN 53_CD ,_, and_CC we_PRP were_VBD able_JJ to_TO show_VB
        that_IN this_DT was_VBD dependent_JJ on_IN prior_JJ phosphorylation_NN of_IN serine_NN
        37_CD by_IN DNA-PK_NNP ._. We_PRP also_RB examined_VBD if_IN GSK_NNP 3_CD β_NN regulates_VBZ 
        in_IN vivo_NN p_NN 53_CD function_NN through_IN a_DT
        mechanism_NN involving_VBG serines_NNS 33_CD and_CC 37_CD of_IN p_NN 53_CD ._. Previous_JJ
        studies_NNS have_VBP shown_VBN that_DT phosphorylation_NN of_IN serines_NNS 15_CD ,_, 20_CD ,_,
        33_CD and_CC 37_CD of_IN p_NN 53_CD block_VB the_DT interaction_NN of_IN p_NN 53_CD with_IN mdm_NN 2_CD ,_,
        leading_VBG to_TO stabilization_NN and_CC accumulation_NN of_IN p_NN 53_CD protein_NN in_IN
        the_DT cell_NN [_NN 10_CD ,_, 11_CD ,_, 13_CD ,_, 14_CD ,_, 15_CD ,_, 18_CD ]_NN ._. mdm_NN 2_CD binding_JJ is_VBZ
        dependent_JJ on_IN the_DT phosphorylation_NN status_NN of_IN serine_NN 20_CD of_IN p_NN 53_CD
        [_NN 15_CD ]_NN ,_, although_IN phosphorylation_NN of_IN serines_NNS 15_CD ,_, 33_CD and_CC 37_CD
        also_RB play_VB a_DT role_NN ._. We_PRP did_VBD not_RB detect_VB any_DT significant_JJ
        difference_NN in_IN the_DT level_NN of_IN expression_NN of_IN p_NN 53_CD with_IN single_JJ
        mutations_NNS in_IN either_DT serines_NNS 33_CD or_CC 37_CD when_WRB compared_VBN to_TO
        wtp_NN 53_CD ,_, indicating_VBG that_IN single_JJ point_NN mutations_NNS in_IN serines_NNS 33_CD
        or_CC 37_CD do_VBP not_RB greatly_RB alter_VB p_NN 53_CD stability_NN ._.
        A_DT key_JJ function_NN of_IN p_NN 53_CD is_VBZ the_DT transcriptional_NN activation_NN
        of_IN genes_NNS which_WDT regulate_VB growth_NN arrest_NN and_CC apoptosis_NNS [_NN 1_CD ,_, 2_CD ,_,
        3_CD ,_, 4_CD ]_NN ._. Individual_JJ mutation_NN of_IN either_DT serine_NN 33_CD or_CC 37_CD
        slightly_RB increased_VBD the_DT basal_NN transcriptional_NN activity_NN of_IN
        the_DT p_NN 53_CD protein_NN ._. This_DT is_VBZ in_IN keeping_VBG with_IN observations_NNS made_VBN
        by_IN other_JJ groups_NNS ,_, who_WP demonstrated_VBD that_IN single_JJ or_CC multiple_JJ
        mutations_NNS in_IN p_NN 53_CD phosphorylation_NN sites_NNS has_VBZ minimal_JJ effect_NN
        on_IN the_DT basal_NN transcriptional_NN activity_NN of_IN the_DT p_NN 53_CD protein_NN [_NN
        38_CD ,_, 39_CD ,_, 40_CD ]_NN ._. We_PRP also_RB determined_VBD if_IN GSK_NNP 3_CD β_NN could_MD regulate_VB p_NN 53_CD
        transcriptional_NN activity_NN 
        in_IN vivo_NN ._. GSK_NNP 3_CD β_NN is_VBZ constitutively_RB
        active_JJ in_IN resting_VBG cells_NNS ,_, but_CC exhibits_VBZ lower_JJR activity_NN in_IN
        asynchronously_RB growing_VBG cells_NNS [_NN 24_CD ]_NN ._. To_TO increase_VB the_DT
        activity_NN of_IN GSK_NNP 3_CD β_NN ,_, we_PRP co-transfected_JJ GSK_NNP 3_CD β_NN with_IN either_DT
        wtp_NN 53_CD or_CC p_NN 53_CD bearing_NN serine_NN to_TO alanine_NN mutations_NNS at_IN
        positions_NNS 33_CD or_CC 37_CD ._. GSK_NNP 3_CD β_NN increased_VBD the_DT transcriptional_NN
        activity_NN of_IN wtp_NN 53_CD ,_, but_CC not_RB of_IN p_NN 53_CD with_IN mutations_NNS in_IN either_DT
        serine_NN 33_CD or_CC 37_CD ._. Therefore_RB both_DT serine_NN 33_CD and_CC serine_NN 37_CD are_VBP
        required_VBN for_IN GSK_NNP 3_CD β_NN to_TO activate_VBP p_NN 53_CD transcriptional_NN activity_NN
        
        in_IN vivo_NN ._. GSK_NNP 3_CD β_NN regulates_VBZ many_JJ stress_NN
        activated_VBN transcription_NN factors_NNS ._. For_IN example_NN ,_, GSK_NNP 3_CD β_NN is_VBZ
        required_VBN for_IN activation_NN of_IN NFκ_NNP B_NNP [_NN 37_CD ]_NN ,_, but_CC inhibits_NNS
        activation_NN of_IN Heat_NNP Shock_NN Factor-_NNP 1_CD [_NN 27_CD ]_NN ._. Our_PRP$ results_NNS
        indicate_VBP that_IN GSK_NNP 3_CD β_NN may_MD also_RB be_VB involved_VBN in_IN the_DT activation_NN
        of_IN the_DT p_NN 53_CD protein_NN as_RB well_RB ._.
        A_DT key_JJ question_NN is_VBZ whether_IN DNA-PK_NNP or_CC some_DT other_JJ kinase_NN
        phosphorylates_NNS serine_NN 37_CD of_IN p_NN 53_CD 
        in_IN vivo_NN ._. DNA-PK_NNP is_VBZ 460_CD kd_NN
        DNA-activated_NNP protein_NN kinase_NN which_WDT participates_VBZ in_IN the_DT
        cellular_JJ response_NN to_TO DNA_NNP damage_NN [_NN 41_CD ]_NN ._. DNA-PK_NNP is_VBZ involved_VBN
        in_IN DNA_NNP strand-break_JJ repair_NN ,_, and_CC can_MD phosphorylate_NN serines_NNS
        15_CD and_CC serine_NN 37_CD of_IN p_NN 53_CD 
        in_IN vitro_NN [_NN 32_CD ]_NN ._. Some_DT reports_NNS indicate_VBP
        that_IN DNA-PK_NNP is_VBZ required_VBN for_IN the_DT activation_NN of_IN p_NN 53_CD [_NN 42_CD ]_NN ,_,
        but_CC recent_JJ genetic_JJ studies_NNS have_VBP shown_VBN clearly_RB that_IN DNA-PK_NNP
        is_VBZ not_RB required_VBN for_IN p_NN 53_CD activation_NN by_IN Ionizing_NNP Radiation_NNP [_NN
        43_CD ]_NN ._. Whether_IN DNA-PK_NNP is_VBZ required_VBN for_IN p_NN 53_CD activation_NN in_IN
        response_NN to_TO other_JJ stimuli_NNS is_VBZ not_RB known_VBN ._. A_DT more_RBR likely_JJ
        candidate_NN is_VBZ the_DT Atr_NNP protein_NN kinase_NN ,_, a_DT kinase_NN related_VBN to_TO
        DNA-PK_NNP [_NN 44_CD ]_NN ,_, which_WDT can_MD regulate_VB the_DT phosphorylation_NN of_IN
        serine_NN 37_CD of_IN p_NN 53_CD in_IN response_NN to_TO DNA_NNP damage_NN ._. The_DT present_JJ
        data_NN indicates_VBZ that_DT transcriptional_NN activation_NN of_IN p_NN 53_CD by_IN
        GSK_NNP 3_CD β_NN requires_VBZ both_DT serines_NNS 33_CD and_CC 37_CD ,_, but_CC it_PRP does_VBZ not_RB
        allow_VB us_PRP to_TO determine_VB if_IN phosphorylation_NN of_IN serine_NN 33_CD is_VBZ
        dependent_JJ on_IN phosphorylation_NN of_IN serine_NN 37_CD 
        in_IN vivo_NN ._. It_PRP is_VBZ possible_JJ that_IN ,_, 
        in_IN vivo_NN ,_, GSK_NNP 3_CD β_NN directly_RB
        phosphorylates_NNS serine_NN 33_CD independently_RB of_IN serine_NN 37_CD ,_, but_CC
        that_IN both_DT residues_NNS must_MD be_VB phosphorylated_JJ for_IN
        transcriptional_NN activation_NN to_TO occur_VB 
        in_IN vivo_NN ._. Future_JJ studies_NNS will_MD address_VB
        this_DT issue_NN ._.
        p_NN 53_CD is_VBZ activated_VBN by_IN multiple_JJ pathways_NNS ,_, including_VBG DNA_NNP
        damage_NN and_CC oncogene_NN activation_NN [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ._. If_IN GSK_NNP 3_CD β_NN is_VBZ
        required_VBN for_IN the_DT activation_NN of_IN p_NN 53_CD by_IN DNA_NNP damage_NN ,_, GSK_NNP 3_CD β_NN
        activity_NN should_MD be_VB regulated_VBN by_IN DNA_NNP damage_NN ._. However_RB ,_, when_WRB
        cells_NNS were_VBD exposed_VBN to_TO Ionizing_NNP Radiation_NNP ,_, GSK_NNP 3_CD β_NN kinase_NN
        activity_NN was_VBD inhibited_VBD rather_RB than_IN enhanced_VBN ,_, implying_VBG
        decreased_VBN GSK_NNP 3_CD β-dependent_JJ phosphorylation_NN of_IN p_NN 53_CD after_IN DNA_NNP
        damage_NN ._. Serine_NNP 33_CD of_IN p_NN 53_CD is_VBZ also_RB phosphorylated_JJ by_IN other_JJ
        kinases_NNS ,_, including_VBG the_DT CDK_NNP 7_CD -_: cyclin_NN H_NNP complex_JJ [_NN 45_CD ]_NN and_CC p_NN 38_CD
        MAPK_NNP [_NN 46_CD ]_NN ._. p_NN 38_CD MAPK_NNP is_VBZ involved_VBN in_IN p_NN 53_CD activation_NN by_IN
        genotoxic_JJ stress_NN [_NN 46_CD ]_NN ,_, and_CC may_MD be_VB responsible_JJ for_IN p_NN 53_CD
        phosphorylation_NN at_IN serine_NN 33_CD in_IN response_NN to_TO DNA_NNP damage_NN ._.
        GSK_NNP 3_CD β-dependent_JJ phosphorylation_NN of_IN p_NN 53_CD at_IN serine_NN 33_CD may_MD be_VB
        part_NN of_IN other_JJ p_NN 53_CD -_: regulatory_JJ pathways_NNS ,_, such_JJ as_IN oncogene_NN
        activation_NN or_CC apoptosis_NNS ,_, which_WDT are_VBP not_RB directly_RB activated_VBN
        by_IN DNA-damage_NNP ._. For_IN example_NN ,_, activation_NN of_IN the_DT p_NN 110_CD -_: PI_NNP
        3_CD -_: kinase_NN /_NN PKB_NNP pathway_NN delivers_VBZ an_DT anti-apoptotic_JJ signal_NN to_TO
        the_DT cell_NN [_NN 23_CD ,_, 25_CD ,_, 47_CD ]_NN ._. Further_RB ,_, activation_NN of_IN the_DT p_NN 110_CD -_: PI_NNP
        3_CD -_: kinase_NN /_NN PKB_NNP is_VBZ associated_VBN with_IN inhibition_NN of_IN both_DT p_NN 53_CD
        dependent_JJ apoptosis_NNS [_NN 48_CD ]_NN and_CC p_NN 53_CD transcriptional_NN activity_NN
        [_NN 49_CD ,_, 50_CD ]_NN ._. Although_IN PKB_NNP has_VBZ many_JJ down_RP stream_NN targets_NNS which_WDT
        may_MD regulate_VB these_DT effects_NNS [_NN 47_CD ]_NN a_DT key_JJ target_NN of_IN PKB_NNP is_VBZ
        GSK_NNP 3_CD β_NN [_NN 29_CD ]_NN ._. Phosphorylation_NNP of_IN GSK_NNP 3_CD β_NN by_IN PKB_NNP inhibits_NNS GSK_NNP 3_CD β_NN
        kinase_NN activity_NN [_NN 29_CD ]_NN ._. This_DT would_MD be_VB predicted_VBN to_TO block_VB
        phosphorylation_NN of_IN serine_NN 33_CD of_IN p_NN 53_CD by_IN GSK_NNP 3_CD β_NN ,_, decreasing_VBG
        p_NN 53_CD transcriptional_NN activity_NN and_CC therefore_RB reducing_VBG the_DT
        transcription_NN of_IN p_NN 53_CD -_: regulated_VBN growth_NN and_CC pro-apoptotic_JJ
        proteins_NNS ._. However_RB ,_, clarification_NN of_IN the_DT potential_JJ role_NN of_IN
        GSK_NNP 3_CD β_NN in_IN regulating_VBG p_NN 53_CD activation_NN by_IN non-_NN DNA_NNP damage_NN
        pathways_NNS will_MD require_VB additional_JJ study_NN ._.
      
      
        Conclusions_NNP
        This_DT study_NN demonstrates_VBZ that_IN GSK_NNP 3_CD β_NN ,_, but_CC not_RB GSK_NNP 3_CD α_NN ,_, can_MD
        directly_RB phosphorylate_NN serine_NN 33_CD of_IN p_NN 53_CD when_WRB serine_NN 37_CD of_IN
        p_NN 53_CD is_VBZ already_RB phosphorylated_JJ ._. GSK_NNP 3_CD β_NN can_MD increase_VB p_NN 53_CD 's_POS
        transcriptional_NN activity_NN 
        in_IN vivo_NN ,_, and_CC this_DT activation_NN requires_VBZ
        serines_NNS 33_CD and_CC 37_CD of_IN the_DT p_NN 53_CD protein_NN ._. Thus_RB GSK_NNP 3_CD β_NN may_MD
        phosphorylate_NN and_CC activate_VBP p_NN 53_CD 
        in_IN vivo_NN ._. However_RB ,_, GSK_NNP 3_CD β_NN is_VBZ not_RB part_VB
        of_IN the_DT p_NN 53_CD -_: DNA_NNP damage_NN response_NN pathway_NN ._. Instead_RB ,_, GSK_NNP 3_CD β_NN may_MD
        provide_VB the_DT link_NN between_IN p_NN 53_CD and_CC non-_NN DNA_NNP damage_NN mechanisms_NNS
        for_IN p_NN 53_CD activation_NN ,_, such_JJ as_IN oncogene_NN activation_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Phosphorylation_NNP Reactions_NNP
          Wild_NNP type_NN p_NN 53_CD or_CC p_NN 53_CD bearing_NN mutations_NNS in_IN serines_NNS 33_CD
          or_CC 37_CD were_VBD subcloned_JJ into_IN pGEX-_NN 2_CD T_NN GST_NNP fusion_NN vector_NN
          (_( Pharmacia_NNP ,_, NJ_NNP )_) and_CC p_NN 53_CD -_: GST_NNP purified_JJ as_IN previously_RB
          described_VBD [_NN 33_CD ]_NN ._. p_NN 53_CD -_: GST_NNP protein_NN (_( 2_CD μg_NN ;_: measured_VBN using_VBG
          Bio-_NNP Rad_NNP Protein_NNP assay_NN Kit_NNP ,_, Biorad_NNP ,_, CA_NNP )_) was_VBD incubated_JJ with_IN
          MAP_NNP kinase_NN (_( Erk_NNP 2_CD ,_, 10_CD Units_NNS ,_, New_NNP England_NNP Biolabs_NNP ,_, MA_NNP )_) ,_,
          Protein_NNP Kinase_NNP A_DT (_( Catalytic_NNP sub-unit_JJ ,_, 5_CD Units_NNS ,_,
          Calbiochem_NNP ,_, CA_NNP )_) ,_, S_NNP 6_CD kinase_NN (_( 0_CD ._. 2_LS Units_NNS ,_, Upstate_NNP
          Biotechnology_NNP ,_, NY_NNP )_) ,_, Protein_NNP Kinase_NNP C_NNP (_( O_NNP ._. 1_LS mUnits_NNS ,_, Roche_NNP
          Molecular_NNP Biochemicals_NNP ,_, IN_IN )_) or_CC DNA-PK_NNP (_( 20_CD Units_NNS ,_, Promega_NNP
          Corp_NNP ,_, Wl_NNP )_) for_IN 5_CD h_NN at_IN 30_CD °_NN C_NNP in_IN the_DT following_VBG buffers_NNS (_( 40_CD μl_NN
          final_JJ volume_NN )_) ._. MAP_NNP kinase_NN and_CC Protein_NNP Kinase_NNP A_DT :_: 20_CD mM_NN
          Hepes_NNP pH_NN 7_CD ._. 2_CD /_NN 10_CD mM_NN Na-_NNP Acetate_NNP /_NN 30_CD mM_NN MgCl_NNP 
          2_CD /_NN 0_CD ._. 2_LS mM_NN EDTA_NNP /_NN 1_CD mM_NN EDTA_NNP /_NN I_PRP 0_CD μM_NN ATP_NNP ._. S_NNP 6_CD
          Kinase_NNP :_: 20_CD mM_NN MOPS_NNP pH_NN 7_CD ._. 2_CD /_NN 30_CD mM_NN MgCl_NNP 
          2_CD /_NN 5_CD mM_NN EGTA_NNP /_NN 1_CD mM_NN DTT_NNP /_NN I_PRP 0_CD μM_NN ATP_NNP ._.
          DNA-PK_NNP :_: 25_CD mM_NN Hepes_NNP pH_NN 7_CD ._. 5_LS /_NN 150_CD mM_NN KCI_NNP /_NN 10_CD mM_NN MgCl_NNP 
          2_CD /_NN 20_CD %_NN Glycerol_NNP /_NN 0_CD ._. 1_LS %_NN NP_NNP 40_CD /_NN 20_CD μM_NN ZnCl_NNP 
          2_CD /_NN 1_CD mM_NN DTT_NNP /_NN 250_CD ng_NN DNA_NNP /_NN 4_CD ._. 2_LS mM_NN
          spermidine_NN /_NN 10_CD μM_NN ATP_NNP ._. PKC_NNP :_: 20_CD mM_NN Hepes_NNP pH_NN 7_CD ._. 4_CD /_NN 20_CD mM_NN
          MgCl_NNP 
          2_CD /_NN 0_CD ._. 2_CD mM_NN EGTA_NNP /_NN 1_CD mM_NN CaCl_NNP 
          2_CD /_NN 1_CD ._. 5_LS μg_NN phosphatidylserine_NN ._. Samples_NNP
          were_VBD then_RB incubated_JJ at_IN 65_CD °_NN C_NNP for_IN 20_CD min_NN to_TO inactivate_NN
          kinases_NNS ,_, and_CC 25_CD %_NN of_IN the_DT reaction_NN incubated_JJ for_IN 30_CD min_NN
          with_IN GSK_NNP 3_CD α_NN or_CC GSK_NNP 3_CD β_NN in_IN GSK_NNP 3_CD kinase_NN buffer_NN (_( KGB_NNP Buffer_NNP :_: 8_CD
          mM_NN MOPS_NNP ,_, pH_NN 7_CD ._. 2_LS /_NN 10_CD mM_NN MgCl_NNP 
          2_CD /_NN 0_CD ._. 2_CD mM_NN EDTA_NNP /_NN 5_CD μM_NN ATP_NNP /_NN 10_CD μCi_NN
          32_CD P-ATP_NNP )_) in_IN a_DT final_JJ volume_NN of_IN 40_CD μl_NN ._. Reactions_NNP were_VBD
          terminated_VBN by_IN the_DT addition_NN of_IN SDS_NNP sample_NN buffer_NN and_CC
          p_NN 53_CD -_: GST_NNP phosphorylation_NN detected_VBN by_IN SDS-PAGE_NNP and_CC
          auotradiography_NN ._. Equal_NNP amounts_NNS of_IN p_NN 53_CD -_: GST_NNP (_( 0_CD ._. 25_CD μg_NN )_) were_VBD
          analyzed_VBN by_IN SDS-PAGE_NNP and_CC equal_JJ loading_NN confirmed_VBN by_IN
          coomassie_NN blue_JJ staining_VBG of_IN the_DT SDS-PAG_NNP ._.
        
        
          GSK_NNP 3_CD immunokinase_NN assay_NN
          SAOS-_NNP 2_CD cells_NNS (_( 5_CD ×_NN 10_CD 6_CD )_) were_VBD lyzed_JJ in_IN 0_CD ._. 5_CD ml_NN of_IN GLB_NNP
          buffer_NN (_( 50_CD mM_NN Tris_NNP pH_NN 7_CD ._. 5_LS /_NN 1_CD mM_NN EDTA_NNP /_NN 1_CD mM_NN EGTA_NNP /_NN 0_CD ._. 5_LS %_NN
          NP_NNP 40_CD /_NN 0_CD ._. 5_LS M_NNP NaCI_NNP /_NN 1_CD mM_NN DTT_NNP /_NN 1_CD mM_NN
          PMSF_NNP /_NN leupeptin_NN /_NN aprotinin_NN /_NN 600_CD μM_NN Na_NNP 
          3_CD VO_NNP 
          4_CD /_NN 50_CD mM_NN NaF_NNP )_) ._. Extracts_NNP were_VBD cleared_VBN
          by_IN centrifugation_NN and_CC incubated_JJ with_IN GSK_NNP 3_CD antibody_NN (_( 1_CD μg_NN ;_:
          Upstate_NNP Biotech_NNP ,_, NY_NNP )_) prebound_NN to_TO Sepharose_NNP A_DT /_NN G_NNP agarose_NN
          beads_NNS for_IN 2_CD h_NN ._. The_DT beads_NNS were_VBD washed_VBN in_IN 4_CD ×_NN 1_CD ml_NN of_IN GLB_NNP
          buffer_NN and_CC then_RB in_IN 2_CD ×_NN 1_CD ml_NN of_IN KGB_NNP buffer_NN ._. Kinase_NNP
          reactions_NNS contained_VBD 5_CD μM_NN ATP_NNP /_NN 15_CD μCi_NN 32_CD P-ATP_NNP /_NN 0_CD ._. 5_LS μg_NN
          PhosphoCREB_NNP peptide_NN in_IN 30_CD μl_NN of_IN KGB_NNP ._. After_IN incubate_NN for_IN
          10_CD min_NN at_IN room_NN temperature_NN ,_, the_DT beads_NNS were_VBD collected_VBN by_IN
          centrifugation_NN and_CC 20_CD μl_NN of_IN the_DT reaction_NN mix_NN spotted_VBD onto_IN
          circles_NNS of_IN P_NN 81_CD paper_NN (_( Whatman_NNP ,_, USA_NNP )_) ._. The_DT P_NN 81_CD paper_NN was_VBD
          washed_VBN in_IN 4_CD ×_NN 10_CD ml_NN changes_NNS of_IN 100_CD mM_NN phosphoric_JJ acid_NN ,_,
          dried_VBD and_CC counted_VBN ._. PhosphoCREB_NNP peptide_NN (_( sequence_NN
          KRREILSRRPS_NNP (_( P_NN )_) YR_NNP )_) was_VBD obtained_VBN from_IN New_NNP England_NNP Biolabs_NNP ,_,
          MA_NNP ._.
          
          Mutagenesis_NNP was_VBD carried_VBN out_IN using_VBG the_DT
          Altered_NNP Sites_NNP Mutagenesis_NNP System_NNP (_( Promega_NNP ,_, Wl_NNP )_) as_RB
          previously_RB described_VBN by_IN us_PRP [_NN 33_CD ]_NN ._. Human_NNP wild_JJ type_NN p_NN 53_CD or_CC
          p_NN 53_CD bearing_NN mutations_NNS in_IN serines_NNS 33_CD or_CC 37_CD were_VBD inserted_VBN
          into_IN the_DT BamH_NNP 1_CD site_NN of_IN the_DT pcDNA_NN 3_CD ._. 1_LS expression_NN vector_NN
          (_( Invitrogen_NNP ,_, CA_NNP )_) ._.
          
          Luciferase_NNP reporter_NN assays_NNS were_VBD
          carried_VBN out_IN in_IN the_DT p_NN 53_CD null_NN cell_NN line_NN SAOS-_NNP 2_CD using_VBG the_DT
          p_NN 53_CD specific_JJ luciferase_NN reporter_NN construct_VB p_NN 50_CD -_: Luc_NNP ,_, and_CC
          pCMV-β-galatosidase_JJ to_TO control_VB for_IN transfection_NN
          efficiency_NN ._. Cells_NNP were_VBD transfected_JJ using_VBG Lipofectin_NNP
          (_( Gibco-_NNP BRL_NNP )_) containing_VBG p_NN 50_CD -_: Luc_NNP (_( 1_CD μg_NN )_) ,_, pCMV-Gal_JJ (_( 1_CD μg_NN )_)
          and_CC pcDNAp_NN 53_CD (_( 50_CD ng_NN )_) in_IN a_DT final_JJ volume_NN of_IN 400_CD μl_NN as_IN
          described_VBN in_IN the_DT manufacturers_NNS protocol_NN ._.
        
      
    
  
